kidney
Researchers uncovered serum proteome biomarkers to predict eGFR decline in patients with ADPKD.
Crescents and cellular segmental sclerosis predicted greater benefit from glucocorticoids in IgA nephropathy.
Researchers set out to determine the optimal systolic BP for achieving kidney protection in middle-aged and older patients.
Real-world data provided strong evidence supporting GLP-1 RA use in patients with diabetes receiving dialysis.
A study shed light on the association between childhood cancer treatment and CKD or hypertension after treatment.
A population health management intervention for CKD lowered hospitalization rates but not costs.
We asked five nephrologists: What technology or tool has changed your practice the most in the last 5 years?
The American Society of Nephrology announced details of the plenary sessions scheduled to take place at Kidney Week 2025.
The FDA approved pegcetacoplan for the treatment of C3G and IC-MPGN in adults and children 12 and older.
Desmopressin reduces post-biopsy bleeding and hematoma formation, a study found.
Treatment with SGLT2i demonstrated lower rates of CKD progression to kidney replacement therapy compared with GLP-1RAs.
Research showed a link between SARS-CoV-2 infection and greater CKD risks and other kidney outcomes.
We spoke with George Edward Newman, MD, a site principal investigator of the PREVAIL study of felzartamab in IgAN.
Kidney Care Partners visited called on Congress to support policies benefitting Americans with kidney disease.
Meta-analyses reaffirmed cardiovascular and renal benefits of long-acting GLP-1RAs for patients with type 2 diabetes.
A report based on chart data and specialist surveys reveals gaps in treatment for FSGS but optimism about the drug pipeline.
The FDA has granted Orphan Drug Designation to veverimer for anti–glomerular basement membrane (anti-GBM) disease.
Richard Furie, MD, discussed the REGENCY trial of obinutuzumab in systemic lupus erythematosus and lupus nephritis.
Gene sequencing of a patient with gouty sacroiliitis and gouty nephropathy highlighted genetic factors leading to gout.
Pegcetacoplan reduced proteinuria and stabilized eGFR in adolescent patients with C3G or primary IC-MPGN.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.